Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.
2.

A novel autosomal dominant leukodystrophy with specific MRI pattern.

Corlobé A, Taithe F, Clavelou P, Pierre E, Carra-Dallière C, Ayrignac X, Mouzat K, Lumbroso S, Menjot de Champfleur N, Koenig M, Boespflug-Tanguy O, Labauge P.

J Neurol. 2015 Apr;262(4):988-91. doi: 10.1007/s00415-015-7660-4. Epub 2015 Feb 17.

PMID:
25683759
3.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
4.

Prolonged continuous theta-burst stimulation is more analgesic than 'classical' high frequency repetitive transcranial magnetic stimulation.

Moisset X, Goudeau S, Poindessous-Jazat F, Baudic S, Clavelou P, Bouhassira D.

Brain Stimul. 2015 Jan-Feb;8(1):135-41. doi: 10.1016/j.brs.2014.10.006. Epub 2014 Oct 18.

PMID:
25456979
5.

Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations.

Böhm J, Biancalana V, Malfatti E, Dondaine N, Koch C, Vasli N, Kress W, Strittmatter M, Taratuto AL, Gonorazky H, Laforêt P, Maisonobe T, Olivé M, Gonzalez-Mera L, Fardeau M, Carrière N, Clavelou P, Eymard B, Bitoun M, Rendu J, Fauré J, Weis J, Mandel JL, Romero NB, Laporte J.

Brain. 2014 Dec;137(Pt 12):3160-70. doi: 10.1093/brain/awu272. Epub 2014 Sep 25.

PMID:
25260562
6.

Soluble IL-2 receptor: a biomarker for assessing myositis activity.

Tournadre A, Dubost JJ, Soubrier M, Ruivard M, Souteyrand P, Schmidt J, Clavelou P, Tridon A, Ristori JM.

Dis Markers. 2014;2014:472624. doi: 10.1155/2014/472624. Epub 2014 Feb 4.

7.

Two cases of bilateral amiodarone-associated optic neuropathy.

Chassang B, Bonnin N, Moisset X, Citron B, Clavelou P, Chiambaretta F.

J Fr Ophtalmol. 2014 Mar;37(3):231-6. doi: 10.1016/j.jfo.2013.12.004. Epub 2014 Feb 24.

PMID:
24576569
8.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
9.

Can we optimize our teams? Multidisciplinary care for multiple sclerosis.

Clavelou P.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):39-44. doi: 10.1586/14737175.2013.865873. Review.

PMID:
24289841
10.

Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis.

Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P.

Pain. 2013 Dec;154(12):2691-9. doi: 10.1016/j.pain.2013.07.050. Epub 2013 Aug 2.

PMID:
23911697
11.

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP.

Eur J Neurol. 2014;21(1):40-8. doi: 10.1111/ene.12204. Epub 2013 Jun 12.

PMID:
23895407
12.

Improvement of the management of infants, children and adults with a molecular diagnosis of Enterovirus meningitis during two observational study periods.

Archimbaud C, Ouchchane L, Mirand A, Chambon M, Demeocq F, Labbé A, Laurichesse H, Schmidt J, Clavelou P, Aumaître O, Regagnon C, Bailly JL, Henquell C, Peigue-Lafeuille H.

PLoS One. 2013 Jul 11;8(7):e68571. doi: 10.1371/journal.pone.0068571. Print 2013.

13.

Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.

Clavelou P, Blanquet M, Peyrol F, Ouchchane L, Gerbaud L.

J Neurol Sci. 2013 Aug 15;331(1-2):126-31. doi: 10.1016/j.jns.2013.06.002. Epub 2013 Jun 25.

PMID:
23809193
14.

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, Marin B; RIMAG Study Group (France and Switzerland).

Neurology. 2013 Jun 11;80(24):2217-25. doi: 10.1212/WNL.0b013e318296e92b. Epub 2013 May 10.

15.

Salivary glands radiotherapy to reduce sialorrhea in amyotrophic lateral sclerosis: dose and energy.

Bourry N, Guy N, Achard JL, Verrelle P, Clavelou P, Lapeyre M.

Cancer Radiother. 2013 Jun;17(3):191-5. doi: 10.1016/j.canrad.2013.01.010. Epub 2013 Mar 19.

PMID:
23517881
16.

[Unilateral Creutzfeld-Jakob disease: report of a probable case on electroclinical, MRI and biological criteria].

Moisset X, Vitello N, Cornut-Chauvinc C, Taithe F, Dionet E, Lauxerois M, Guy N, Clavelou P.

Rev Neurol (Paris). 2013 Feb;169(2):162-5. doi: 10.1016/j.neurol.2012.07.019. Epub 2012 Oct 15. French.

PMID:
23079855
17.

Increased risk of multiple sclerosis relapse after in vitro fertilisation.

Michel L, Foucher Y, Vukusic S, Confavreux C, de Sèze J, Brassat D, Clanet M, Clavelou P, Ouallet JC, Brochet B, Pelletier J, Labauge P, Lebrun C, Lepage E, Le Frere F, Jacq-Foucher M, Barriere P, Wiertlewski S, Laplaud DA; Club Francophone de la Sclérose En Plaques (CFSEP).

J Neurol Neurosurg Psychiatry. 2012 Aug;83(8):796-802. doi: 10.1136/jnnp-2012-302235. Epub 2012 Jun 11.

PMID:
22693287
18.

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.

Vermersch P, Benrabah R, Schmidt N, Zéphir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O.

BMC Neurol. 2012 Jun 12;12:36. doi: 10.1186/1471-2377-12-36.

19.

Comparison of radiotherapy types in the treatment of sialorrhea in amyotrophic lateral sclerosis.

Guy N, Bourry N, Dallel R, Dualé C, Verrelle P, Lapeyre M, Clavelou P.

J Palliat Med. 2011 Apr;14(4):391-5. doi: 10.1089/jpm.2010.0308. Epub 2011 Mar 17.

PMID:
21413884
20.

Cancer and multiple sclerosis in the era of disease-modifying treatments.

Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, Debouverie M, de Seze J, Wiertlevsky S, Heinzlef O, Tourbah A, Fromont A, Frenay M.

J Neurol. 2011 Jul;258(7):1304-11. doi: 10.1007/s00415-011-5929-9. Epub 2011 Feb 4.

PMID:
21293872
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk